Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2022 Aug 19;17(8):e0268122. doi: 10.1371/journal.pone.0268122

Antiretroviral therapy initiation and outcomes of hospitalized HIV-infected patients in Uganda—An evaluation of the HIV test and treat strategy

Andrew Katende 1,2,*, Lydia Nakiyingi 1,3, Irene Andia-Biraro 1,4,5, Thomas Katairo 6, Richard Muhumuza 4, Andrew S Ssemata 4, Christopher Nsereko 7, Fred C Semitala 1,6,8, David B Meya 1,3
Editor: Nei-yuan Hsiao9
PMCID: PMC9390910  PMID: 35984779

Abstract

Background

Uganda adopted the HIV Test and Treat in 2016. There is paucity of data about its implementation among hospitalized patients. We aimed to determine the proportion of patients initiating anti-retroviral therapy (ART) during hospitalization, barriers and mortality outcome.

Methods

In this mixed methods cohort study, we enrolled hospitalized patients with a recent HIV diagnosis from three public hospitals in Uganda. We collected data on clinical characteristics, ART initiation and reasons for failure to initiate ART, as well as 30 day outcomes. Healthcare workers in-depth interviews were also conducted and data analyzed by sub-themes.

Results

We enrolled 234 patients; females 140/234 (59.8%), median age 34.5 years (IQR 29–42), 195/234 (83.7%) had WHO HIV stage 3 or 4, and 74/116 (63.8%) had CD4 ≤ 200 cell/μL. The proportion who initiated ART during hospitalization was 123/234 (52.6%) (95% CI 46.0–59.1), of these 35/123 (28.5%) initiated ART on the same day of hospitalization, while 99/123 (80.5%) within a week of hospitalization. By 30 days 34/234 (14.5%) (95% CI 10.3–19.7) died. Patients residing ≥ 35 kilometers from the hospital were more likely not to initiate ART during hospitalization, [aRR = 1.39, (95% CI 1.22–1.59). Inadequate patient preparation for ART initiation and advanced HIV disease were highlighted as barriers of ART initiation during hospitalization.

Conclusion

In this high HIV prevalence setting, only half of newly diagnosed HIV patients are initiated on ART during hospitalization. Inadequate pre-ART patient preparation and advanced HIV are barriers to rapid ART initiation among hospitalized patients in public hospitals.

Introduction

Early ART initiation among people living with HIV (PLHIV) reduces rates of HIV transmission, morbidity and mortality [13]. In 2015, the World Health Organization (WHO) recommended the HIV test-and-treat strategy where immediate ART should be offered to all newly diagnosed PLHIV irrespective of CD4 count [4], similary in 2016 Uganda adopted this strategy [5,6].

The clinical decision to initiate ART among hospitalized patients can be challenging, especially in settings with limited diagnostic capacity to rule out opportunistic infections. Hospitalized patients are commonly symptomatic, more likely to have co-morbidities and organ dysfunction which may complicate immediate ART initiation [7,8]. The unexpected HIV diagnosis during hospitalization causes psychological stress and denial, which might affect the patients’ readiness to accept ART during hospitalization [9]. A cross-sectional study conducted at the National Referral Hospital in Kampala when Ugandan HIV guidelines recommended ART initiation below a CD4 threshold of 200 cells/μL demonstrated that there was a delay to initiate ART among 75% of hospitalized ART-eligible patients [10]. This study further showed that one third of PLHIV died within two weeks. Previous studies have mainly focused on ambulatory patients in outpatient clinics, community-based ART initiation, and key populations to demonstrate the feasibility and benefits of HIV test-and-treat [11,12]. Four years since Uganda adopted the HIV test-and-treat strategy, there remains a paucity of data on ART initiation among hospitalized patients. We therefore, aimed to determine the proportion of public hospital patients initiating ART during hospitalization, their outcomes, and barriers to in-patient ART initiation.

Methods

Study design and setting

Between December 2019 and March 2020, we conducted a mixed methods prospective cohort study in which we enrolled HIV infected patients and healthcare workers (HCW) from three public hospitals in Uganda, namely; Kiruddu Referral hospital (Kiruddu hospital), Entebbe Regional Referral Hospital (Entebbe Hospital) and China-Uganda Friendship Hospital Naguru (Naguru hospital). Kiruddu hospital is a 200-bed capacity hospital located ten kilometers from the city center in Kampala. The hospital has an HIV clinic that manages 300 patients weekly and admits approximately 10 patients with recently diagnosed HIV infection weekly. Entebbe Hospital is a 200-bed capacity hospital located approximately 35 kilometers from Kampala city and has an HIV clinic that cares for almost 200 patients daily. Approximately 6 patients with recently diagnosed HIV infection are hospitalized weekly. Naguru hospital is a 100-bed capacity hospital, located in Kampala and has an outpatient HIV clinic with 300 patients managed daily and about 6 patients hospitalized with recently diagnosed HIV infection.

Study population and participant recruitment

We screened hospitalized patients with a recent HIV diagnosis based on routine hospital HIV screening per national guidelines. Patients were eligible if they were; 12 years or older, ART naïve, hospitalized for ≥24 hours and gave informed consent/ assent to participate in the study. Patients were excluded if they did not have a personal phone or contacts of a next-of-kin to enable 30 day- follow up.

At enrolment, participants were interviewed to obtain information on socio-demographic and clinical data. A follow up interview on the day of discharge or death was used to collect data on ART status and dates of ART initiation. This information was obtained from the patients’ hospital chart, ART card documents and ART pill counts. The 30-day follow up visit was performed via phone call, 30 days from the day of admission. A participant was considered lost to follow-up if they were un-contactable both physically and through daily phone calls over a period of one week. We also conducted in-depth interviews among twelve purposively selected HCW from the three hospitals these included Internal Medicine specialist trainees (n = 4), intern doctors (n = 4), ART nursing officers (n = 2) and HIV counselors (n = 2).

Data management and analysis

Quantitative analysis

A pre-tested questionnaire was used to collect socio-demographic (sex, age, marital status, occupation, education status, residence and monthly income) and clinical data (WHO HIV stage, CD4, ALT, AST, creatinine, hemoglobin) through patient interviews and hospital chart review. Data was entered in Epi-Data Version 4.6 (Denmark) and then exported to STATA software V15.0 (Stata Corp, College Station, TX) for analysis S1 File. Continuous variables were summarized into means and medians. Categorical variables were summarized and tabulated as frequencies and percentages.

The proportion (95% confidence interval) of hospitalized patients with a new HIV diagnosis who initiated ART during hospitalization was calculated as the number of patients initiated on ART out of the total number of patients recruited in the study.

We adopted the modified Poisson regression model with clustered standard errors (clustered at hospital levels) to predict risk ratios (RR). All variables that had p-values < 0.2 from bivariate analysis were considered for multivariate analysis. In the multivariate analysis, variables were considered using backward stepwise method. Variables with a >10% difference between the crude and adjusted prevalence ratios were considered confounders. All variables were considered to be significant when the p-value <0.05.

Qualitative analysis

In-depth interviews using an interview guide lasting between 40–60 minutes were conducted before the quantitative data collection process, all interviews were audio recorded and transcribed verbatim to generate transcripts used in the analysis S2 File. Data analysis started by developing a codebook and scanning through the transcripts to generate codes, sub themes and broad themes. Transcripts review and codebook development was performed in parallel with the data collection. The analysis was accomplished by the first author (AK) together with two social scientists (RM and ASS) by coding the data manually to the point of saturation, where no novel additional information was being collected. Data was analyzed following the thematic analysis approach that allows analytical themes to emerge from the data and to define codes during the process of reading, exploration and coding responses [13,14]. The broad themes represented the main thematic areas that included: (a) understanding of HIV test-and-treat policy, (b) conditions to start ART as per HIV test-and-treat policy, (c) when a newly diagnosed individual should start ART, (d) reasons for not starting ART immediately, (e) factors associated with failure to start ART, (f) facilitators of early ART initiation, (g) challenges in delivering HIV test-and-treat in hospitals and, (h) solutions to the listed problems.

Ethical considerations

This study was approved by the Scientific Review Committee, Department of internal medicine, Makerere University College of Health Sciences. The study was also approved by the School of Medicine Research and Ethics Committee (REC REF 2019–165). It also received clearance from all hospital sites. Written Informed consent was sought and obtained from all participants.

Results

We screened 250 hospitalized patients with a recent HIV diagnosis at three public hospitals of which 234 were found eligible and enrolled in the study, (Fig 1). Of the 234 participants, 120/234 (51.3%) were recruited from Kiruddu hospital, 59/234 (25.2%) from Naguru hospital and 55/234 (23.5%) from Entebbe hospital.

Fig 1. Study profile of hospitalized patients with a recent HIV diagnosis.

Fig 1

* One patient was not assessed for ART status at discharge.

Socio-demographic and clinical characteristics of hospitalized patients with a recent HIV diagnosis

Among the 234 participants, 59.8% were female and the median age was 34.5 years, (IQR 29–42). The majority (93.2%) had at least primary education and were involved in an income-generating activity. More than a third (32%) had a monthly income of less than 26 USD. The majority of participants from Kiruddu Hospital resided more than 35 kilometers from the hospital Table 1.

Table 1. Baseline demographic characteristics of hospitalized patients with a recent HIV diagnosis stratified by study site.

Variable Overall (n = 234) Kiruddu (N = 120) Naguru (n = 59) Entebbe (n = 55)
Age
 <25 years 26 (11.1) 13 (10.8) 3 (5.1) 10 (18.2)
25–49 181 (77.4) 88 (73.3) 48 (81.4) 45 (81.8)
 >50 years 27 (11.5) 19 (15.8) 8 (13.6) 0 (0.0)
Sex
Male 94 (40.2) 47 (39.2) 30 (50.9) 17 (30.9)
Female 140 (59.8) 73 (60.8) 29 (49.2) 38 (69.1)
Distance *
 <35Km 124 (53.0) 33 (27.5) 45 (76.3) 46 (83.6)
 >35Km 110 (47.0) 87 (72.5) 14 (23.7) 9 (16.4)
Marital status
Not married 125 (53.4) 78 (65.0) 35 (59.3) 12 (21.8)
Married 109 (46.6) 42 (35.0) 24 (40.7) 43 (73.2)
Education status
None 16 (6.8) 8 (6.7) 0 (0.0) 8 (14.6)
Primary 95 (40.6) 62 (51.7) 10 (17.0) 23 (41.8)
Secondary 101 (43.2) 43 (35.8) 37 (62.7) 21 (38.2)
Tertiary 22 (9.4) 7 (5.8) 12 (20.3) 3 (5.5)
Occupation
Employed 182 (77.8) 83 (69.2) 50 (84.8) 49 (89.1)
Not employed 52 (22.2) 37 (30.8) 9 (15.3) 6 (10.9)

• Distance in Kilometers from the hospital.

The majority of participants had WHO stage 3 or 4 HIV disease. Half of the participants had a documented CD4 cell count, 116/234 (49.6%) of which 48/116 (41.4%) had CD4 <100 cells/μL. Attending clinicians made a diagnosis of either Tuberculosis in 36/234 (15.4%) or Cryptococcal meningitis in 14/234 (5.9%) of the participants. Almost one-third of the participants had severe anemia (hemoglobin < 8g/dl) Table 2.

Table 2. Baseline clinical characteristics of hospitalized patients with a recent HIV diagnosis stratified by study site.

Variable Overall (n = 234) Kiruddu (N = 120) Naguru (n = 59) Entebbe (n = 55)
Suspected TB or CM
Yes 119 (50.8) 71 (59.2) 25 (42.4) 23 (41.8)
No 115 (49.2) 49 (40.8) 34 (57.6) 32 (58.2)
Needed oxygen therapy
Yes 21 (9.0) 6 (5.0) 12 (20.3) 3 (5.5)
No 213 (91.0) 114 (95.0) 47 (79.7) 52 (94.6)
Able to self-feed
Yes 204 (87.2) 99 (82.5) 52 (88.1) 53 (96.4)
No 30 (12.8) 21 (17.5) 7 (11.9) 2 (3.6)
HIV WHO stage
1 to 2 38 (16.3) 11 (9.2) 11 (18.6) 16 (29.1)
3 to 4 195 (83.7) 108 (90.8) 48 (81.4) 39 (70.9)
CD4 (cell/mm3)
<200 74 (63.8) 63 (76.8) 0 (0.0) 11 (32.4)
200–499 36 (31.0) 17 (20.7) 0 (0.0) 19 (55.9)
>500 6 (5.2) 2 (2.4) 0 (0.0) 4 (11.8)
Hb (g/dl) 10.0 (7.7, 11.0) 9.9 (7.4, 11.0) 10 (7.0, 12.0) 10.0 (9.0, 11.0)
Creatinine (μmol/L) 84 (61, 104) 75 (52, 98.9) 84 (69, 105) 98 (87, 114)

ART initiation during hospitalization and 30-day outcomes

The median time from admission to HIV testing was 1 day (IQR 1–2) and the median time of hospitalization was 5 days (IQR 3–7). The proportion of participants who initiated ART during hospitalization was 123/234, 52.6%, (95% CI 46.0–59.1) and the median time from admission to ART initiation was 4 days (IQR 1–11). Cumulatively 35/123, 28.5%, (95% CI 20.7–37.3) had initiated ART by day one of hospitalization; 99/123, 80.5%, (95% CI 72.4–87.1) had initiated by day 7 and 113/123, 91.9%, (95% CI 85.6–96) by day 14.

After 30 days of follow up, 19/234 (8.1%) were lost to follow up, 34/234 (14.5%) (95% CI 10.3–19.7) died, 30/234 (12.8%) more patients had initiated ART since discharge, making the overall proportion of participants on ART after 30 days 146/215, (67.9%). Over two-thirds of deaths 22/34 (64.7%) occurred during hospitalization. Mortality among patients who did not initiate ART during hospitalization was significantly higher compared to those who started ART during hospitalization [32/110 29.1% (95% CI 20.8–38.5) versus 2/123, 1.6% (95% CI 20.6–38.2), p-value < 0.001)].

Factors associated with failure to initiate ART during hospitalization

Among the 234 participants, 110 did not start ART during their stay in the hospital, 47%, (95% CI 40.5–53.6). Nearly a third were either too sick or died before starting ART, the main reason for not starting ART was being diagnosed with either Tuberculosis or cryptococcal meningitis. Approximately one in every five of the participants 25/110 (22.7%) opted not to start ART during hospitalization. Overall ART unavailability was the least common reason for not starting ART during hospitalization Table 3.

Table 3. Reasons for not initiating ART during hospitalization stratified by study site.

Reason for not initiating ART Overall (n = 110) Kiruddu (n = 66) Naguru (n = 28) Entebbe (n = 16)
Confirmed TB/CM 50 (45.5) 38 (57.6) 4 (14.2) 8 (50.0)
ART unavailability 1 (0.91) 0 (0.0) 1 (3.6) 0 (0.0)
Opted to Start from a different ART clinic 10 (9.1) 3 (4.6) 6 (21.4) 1 (6.3)
Declined ART when offered 15 (13.6) 7 (10.6) 6 (21.4) 2 (12.5)
Died before starting ART 22 (20.0) 14 (21.2) 4 (14.3) 4 (25.0)
Too sick to start ART 8 (7.3) 2 (3.0) 5 (17.9) 1 (6.3)
No necessary lab workup 4 (3.6) 2 (3.0) 2 (7.1) 0 (0.0)

In the bivariate analysis, participants’ distance from the hospital, education status, being on oxygen therapy, occupation status, and WHO HIV staging were were significantly associated with not initiating ART during hospitalization Table 4.

Table 4. Multivariate analysis for predictors of failure to initiate ART during hospitalization.

Variable Started (n = 123) Not started (n = 110)* RR P-value aRR 95% CI P-value
Age
<25 years 11 (8.9) 15 (13.6) 1
25–49 100 (81.3) 80 (72.7) 0.77 0.083
>50 years 12 (9.8) 15 (13.6) 0.96 0.905
Sex
Male 45 (36.6) 48 (43.6) 1
Female 78 (63.4) 62 (56.4) 0.86 0.095
Distance from hospital
<35KM 74 (60.2) 50 (45.5) 1 1
>35KM 49 (39.8) 60 (54.6) 1.37 <0.001 1.39 1.22, 1.59 <0.001
Marital status
No partner 64 (52.0) 60 (54.6) 1
Partner 59 (48.0) 50 (45.5) 0.95 0.599
Education status
None 5 (4.1) 11 (10.0) 1 1
Primary 50 (40.7) 45 (40.9) 0.69 <0.001 0.68 0.59, 0.78 <0.001
Secondary 55 (44.7) 46 (41.8) 0.66 <0.001 0.66 0.60, 0.73 <0.001
Tertiary 13 (10.6) 8 (7.3) 0.55 0.074 0.57 0.31, 1.04 0.065
Occupation
Not employed 25 (20.3) 27 (24.6) 1
Employed 98 (79.7) 83 (75.5) 0.88 <0.001
Income
<100000 35 (28.5) 40 (36.4) 1
100000–500000 83 (67.5) 60 (54.6) 0.79 0.12
>500000 5 (4.1) 10 (9.1) 1.25 0.279
WHO staging
1 to 2 33 (26,8) 5 (4.6) 1
3 to 4 90 (73.2) 104 (95.4) 4.07 0.001
Oxygen Therapy
Yes 3 (2.4) 18 (16.4) 1 1
No 120 (97.6) 92 (83.6) 0.51 <0.001 0.49 0.37, 0.65 <0.001
Baseline Hb (g/dl) 10.0 (9.0, 11.4) 8.9 (6.6, 11.0) 0.9 0.149

* one participant was not assessed for ART status hence N = 233.

However, when included in the multivariate model, residing more than 35 km away from the hospital was a predictor for not starting ART during hospitalization compared to those residing within the 35 km, [aRR = 1.39, (95% CI 1.22–1.59); p-value <0.001]. Having atleast primary education, [aRR = 0.68, (95% CI 0.59, 0.78); p-value 0.001] and being on Oxgyen therapy, [aRR = 0.49, (95% CI 0.37, 0.65); p-value <0.001] were also predictors for not initiating ART during hospitalization.

Qualitative findings: Barriers to initiating ART during hospitalization

The HCWs factors hindering ART initiation during hospitalization were categorized into; i) patient related, ii) healthcare worker related, and iii) system related factors.

Patient related factors: Stigma, knowledge, and family support

All HCWs were certain that these factors affected patients’ preparedness and readiness to accept ART when offered. They reported that due to the surprise surrounding this diagnosis, patients typically deny their positive HIV test results due to the limited knowledge about HIV and the perceived stigma around HIV. They also highlighted that patients without good family social support were unlikely to start ART during hospitalization.

“Some patients are not willing to start the ARVs at that time. They want to seek a second opinion before they start the ART. Some of them want to first be given time and they think through it since it is a lifelong treatment. Some patients are not ready, they are hesitant to start on it there and then”

(Internal Medicine specialist trainee)

Healthcare worker related factors: Knowledge, limited human resource, and work overload

Inadequate practical knowledge on the approach and benefits of early ART initiation among the very sick hospitalized patients was highlighted as a barrier. Many healthcare workers lacked refresher training about current ART guidelines, lacked the confidence to initiate ART partly due to the previously observed experience of ART related toxicities among sick patients while others especially the junior doctors, did not consider ART as an emergency.

“Some healthcare workers just hear about the HIV test-and-treat but they do not know what entails in that policy, so there is a lack of knowledge about it. And then the other important thing is that sometimes there is ‘inertia’. You diagnose somebody and you just say that let me start on them (ARVS) next week.

(Internal Medicine specialist trainee)

Healthcare workers (10/12) felt the workload was too much for them to offer comprehensive HIV care for hospitalized patients. While the counselors and ART nurses on the ward reported a lack of sufficient time to prepare patients for ART initiation, the clinicians noted that they had many other patients on the wards to attend to.

If it is only one person talking to many people sometimes you get tired and you miss out some information and someone does not get satisfied and he will say that I will not take ART”

(ART nursing officer)

System related factors: Pre-ART initiation laboratory workup, linkage facilitators, ART availability

Nearly all HCWs noted that health facilities do not offer ART services over the weekend. This implied that if a decision to start ART was made during the weekend, patients had to either wait till Monday or be discharged without initiating ART. The majority of patients opted to be discharged without ART promising to return to the outpatient clinic. There were no linkage facilitators to ensure all patients newly diagnosed and opting to start ART from a different center were not lost to follow up.

“We should try as much as possible to have those services 7 days a week because you find that patients who come on weekends will have to wait until Monday to have an HIV test done, so they will have missed two or three days while they are in hospital, and also the other thing is the availability of drugs because you find that if you happen to do the test on weekend and the patients is really positive, drugs are not available.

(Intern medicine specialist trainee)

The lack of consistently available free laboratory testing services in public health facilities was highlighted as one of the commonest reasons for delayed ART initiation in the hospital. Patients having to incur costs to do laboratory tests deemed necessary prior to starting ART including liver and kidney function was a hindrance since the majority of patients had limited financial capacity to pay for these tests. This contributed to delays in ART initiation or missed opportunities to initiate ART during hospitalization.

“Unfortunately most of the patients who come, who are “ISS” (HIV-infected) tend not to have money so that’s where it goes strange, you get constrained. If the patient is a little clinically stable, it means you have to send them home, to come back for review in the clinic with some of those labs, so mostly you find that they end up being initiated in the outpatient clinics.

(Intern Doctor)

Discussion

In this prospective mixed methods study, we found that just over half (52.6%) of the hospitalized patients recently diagnosed with HIV infection initiated ART during hospitalization and only a minority (28.5%) initiated ART within 24 hrs of admission and testing. The majority (64%) presented with advanced HIV disease. The overall all-cause 30-day mortality was 14.5%, and most deaths occurred during hospitalization. Barriers to ART initiation were mainly related to the complexities of dealing with very sick patients who presented with advanced HIV disease and poor in-patient pre-ART preparation.

To our knowledge, since the rollout of the HIV test-and-treat policy no other prospective studies in Uganda have estimated ART initiation specifically among hospitalized patients recently diagnosed with HIV infection. In our study, the proportion of patients with a new HIV diagnosis who started ART while hospitalized (52.6%) was comparably higher than previously reported in a retrospective study in Mulago National Referral Hospital, however, the criteria to initiate ART was notably different in the two studies. Only 5.7% of ART eligible patients had initiated ART during their time of hospitalization and only 20% had initiated ART within 2 weeks in the retrospective study [10]. These high proportions we found are likely explained by the change of ART initiation practice among HCWs following the adoption of new national guidelines since 2016, recommending immediate ART initiation irrespective of CD4 count [5].

Our study also found that only 28.5% started ART within 24 hours of admission or the day they received their HIV test result (same day initiation) and 91.9% had started within 2 weeks, this finding is comparable to retrospective studies conducted in sub Saharan Africa, which assessed ART initiation among PLHIV in out-patient and in-patient settings [15,16]. In a retrospective study conducted in South Africa reviewing routine data since the rollout of HIV test and treat in 2017, the proportion of PLHIV that had initiated ART on the same day was 30.3% in 2017, however, this increased to 54.2% in 2018 [15].

Overall rapid ART initiation remains relatively low among hospitalized adults, despite free access to ART in most low and middle income countries, however, among special groups including pregnant women, the proportion starting ART on the same day is higher than adults in the general HIV population in the same age group [17]. These low proportions of same day ART initiators among hospitalized patients from our study is likely due to interacting factors. First, the proportion of patients admitted with advanced HIV disease was high, this is similar to what other studies in LMICs have found [1820], the current HIV treatment guidelines The current WHO guidelines for initiation of ART among patients with HIV suspected to have TB should initiate ART as soon as possible. In those with confirmed TB, ART should be initiated as soon as possible within 2 weeks of starting Anti-TB drugs. Exception is made in patients suspected to have TB or cryptococcal meningitis; ART should be delayed at least until 4 weeks after initiating treatment [4,6,20,21]. Second, the complexities in managing patients with advanced HIV disease creates clinical challenges for healthcare workers making it difficult to decide to initiate early ART [2225], this was partly supported by the significant proportion of patients (27.3%) who died before starting ART or the attending clinician felt they were too sick to start ART. Third, the challenges in obtaining pre-ART laboratory workup including test stock outs and long turnaround time affect rapid ART initiation in hospitalized patients. Finally, a significant proportion (22.7%) of ART eligible patients opt not to start ART when it is offered and this is partly attributed to system factors like lack of privacy in the open model hospital wards, limited human resource and thus limited time spent interacting with the patient, this negatively impacts the patient-healthcare worker ART initiation preparation process, thus affecting their readiness to initiate ART [2628]. Patient factors like lack of formal education, influences their awareness and knowledge about benefits of early ART initiation, [29]. Since our study was conducted in referral hospitals, many patients coming from distant areas were less likely to start ART in hospital, the HCW reported such patients request to seek second opinion from health facilities near their homes, or promise to start ART from facilities next to their homes.

The all-cause mortality from our study is comparably lower than published studies from similar settings prior to the HIV test-and-treat policy [10,30]. In a retrospective chart review conducted at the National Referral Hospital before the adoption of the test-and-treat, HIV/AIDS was the leading cause of death, with an attributed case fatality rate of 25%. Our mortality rate is also lower than the 26.3% previously reported in a prospective study among hospitalized patients in a tertiary hospital in Lilongwe, Malawi among ART naïve patients or 32.9% among new ART initiators in which TB and Cryptococcal meningitis had the highest case fatality rates [31].

This is the first study in Uganda since the rollout of the HIV test-and-treat strategy in 2016 that specifically attempts to broadly characterize ART initiation, explore the barriers to implementation among hospitalized patients with advanced HIV disease. We believe our findings could be useful in planning and developing strategies towards eliminating AIDS related deaths. However, the study had some limitations mainly from recruiting participants from referral hospitals that tend to have very sick patients needing complex clinical care. Our methods of measuring post discharge outcomes through phone interviews may not be as robust as physical home visits. Only half of the participants had a CD4 measurment. Although this was an observational study that was not powered to examine the mortality difference between the two patients groups, we nevertheless found significantly lower mortality among those who initiated ART during hospitalization similar to what has been previously published by the AIDS Clinical Trial Group (ACTG 5164) and the IDEAL-study [32,33]. We cannot exclude the impact of the Hawthorne effect on our study, thus, our results should be generalized to other hospital settings with caution.

Conclusion

Early ART initiation following the HIV test-and-treat strategy is feasible, however, challenges to adhere to this strategy remain, especially among hospitalized patients with advanced HIV disease who contribute to HIV-related mortality. Inadequate staffing and inadequate healthcare workers’ knowledge around the complexities of care for patients with advanced HIV disease further contributes to this missed opportunity to rapidly initiate ART as a strategy to minimize HIV-related mortality.

Supporting information

S1 File. STaTa data set.

(ZIP)

S2 File. Health care worker interview guide.

(DOCX)

Acknowledgments

We would like to extend our sincere thanks to the participants, both patients and the health care workers for sparing time to participate in the study. Much appreciation goes to the research assistants Esther Kasirye, Richard Sebulime and Hawa Namulondo for their efforts towards making this study a reality.

Data Availability

Due to the small sample size and the detailed content of the interview transcripts, including sensitive and potentially identifying information. The Makerere University, school of Medicne research ethics committee does not approve public release of this type of data. However data supporting the findings of this study will be available upon reasonable request to the the corresponding author. All relevant quantitative data are within the manuscript and its Supporting information files. A quantitative data stata data set has been uploaded as Supporting information. Requests for Qualitative data can be sent to the Makerere School of Medicine Research Ethical Committee, rresearch9@gmail.com or research@chs.mak.ac.ug.

Funding Statement

This work is supported by the Fogarty International Center of the National Institutes of Health under Award Number D43 TW010037. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

References

  • 1.Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365: 493–505. doi: 10.1056/NEJMoa1105243 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, et al. (2015) Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med 373: 795–807. doi: 10.1056/NEJMoa1506816 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, et al. (2015) A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med 373: 808–822. doi: 10.1056/NEJMoa1507198 [DOI] [PubMed] [Google Scholar]
  • 4.WHO (2015) Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV.: World Health Organization. [PubMed]
  • 5.MoH (2016) Consolidated Guidelines For Prevention and Treatment Of HIV in Uganda. MINISTRY OF HEALTH.
  • 6.MoH (2018) CONSOLIDATED GUIDELINES FOR THE PREVENTION AND TREATMENT OF HIV AND AIDS IN UGANDA
  • 7.Namutebi AM, Kamya MR, Byakika-Kibwika P (2013) Causes and outcome of hospitalization among HIV-infected adults receiving antiretroviral therapy in Mulago hospital, Uganda. Afr Health Sci 13: 977–985. doi: 10.4314/ahs.v13i4.17 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Ndagije H, Nambasa V, Namagala E, Nassali H, Kajungu D, et al. (2015) Targeted spontaneous reporting of suspected renal toxicity in patients undergoing highly active anti-retroviral therapy in two public health facilities in Uganda. Drug Saf 38: 395–408. doi: 10.1007/s40264-015-0277-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Nash D, Tymejczyk O, Gadisa T, Kulkarni SG, Hoffman S, et al. (2016) Factors associated with initiation of antiretroviral therapy in the advanced stages of HIV infection in six Ethiopian HIV clinics, 2012 to 2013. J Int AIDS Soc 19: 20637. doi: 10.7448/IAS.19.1.20637 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Ingabire PM, Semitala F, Kamya MR, Nakanjako D (2019) Delayed Antiretroviral Therapy (ART) Initiation among Hospitalized Adults in a Resource-Limited Settings: A Challenge to the Global Target of ART for 90% of HIV-Infected Individuals. 2019: 1832152. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Shade SB, Osmand T, Luo A, Aine R, Assurah E, et al. (2018) Costs of streamlined HIV care delivery in rural Ugandan and Kenyan clinics in the SEARCH Studys. Aids 32: 2179–2188. doi: 10.1097/QAD.0000000000001958 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Amanyire G, Semitala FC, Namusobya J, Katuramu R, Kampiire L, et al. (2016) Effects of a multicomponent intervention to streamline initiation of antiretroviral therapy in Africa: a stepped-wedge cluster-randomised trial. Lancet HIV 3: e539–e548. doi: 10.1016/S2352-3018(16)30090-X [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Mack N, Woodsong C, MacQueen KM, Guest G, Namey E (2005) Qualitative research methods: A data collector’s field guide: Family Health International.
  • 14.Myers G, Macnaghten P (2001) Can focus groups be analysed as talk? In: Barbour R, Kitzinger J, editors. In Developing Focus Group Research: Politics, Theory and Practice. London: SAGE Publications. [Google Scholar]
  • 15.Lilian RR, Rees K, McIntyre JA, Struthers HE, Peters RPH (2020) Same-day antiretroviral therapy initiation for HIV-infected adults in South Africa: Analysis of routine data. 15: e0227572. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Rufu A, Chitimbire VTS, Nzou C, Timire C, Owiti P, et al. (2018) Implementation of the ’Test and Treat’ policy for newly diagnosed people living with HIV in Zimbabwe in 2017. Public Health Action 8: 145–150. doi: 10.5588/pha.18.0030 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Langwenya N, Phillips TK, Brittain K, Zerbe A, Abrams EJ, et al. (2018) Same-day antiretroviral therapy (ART) initiation in pregnancy is not associated with viral suppression or engagement in care: A cohort study. J Int AIDS Soc 21: e25133. doi: 10.1002/jia2.25133 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Siika A, McCabe L, Bwakura-Dangarembizi M, Kityo C, Mallewa J, et al. (2018) Late Presentation With HIV in Africa: Phenotypes, Risk, and Risk Stratification in the REALITY Trial. Clin Infect Dis 66: S140–s146. doi: 10.1093/cid/cix1142 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Tenforde MW, Walker AS (2019) Rapid antiretroviral therapy initiation in low- and middle-income countries: A resource-based approach. 16: e1002723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Lamp K, McGovern S, Fong Y, Atem CD, Nfetam JBE, et al. (2020) Proportions of CD4 test results indicating advanced HIV disease remain consistently high at primary health care facilities across four high HIV burden countries. 15: e0226987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.WHO (2017) Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. Geneva, Switzerland: World Health Organizaton. [PubMed]
  • 22.Nhassengo P, Cataldo F (2018) Barriers and facilitators to the uptake of Test and Treat in Mozambique: A qualitative study on patient and provider perceptions. 13: e0205919. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Calmy A, Ford N, Meintjes G (2018) The Persistent Challenge of Advanced HIV Disease and AIDS in the Era of Antiretroviral Therapy. Clinical Infectious Diseases 66: S103–SS105. doi: 10.1093/cid/cix1138 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Ford N, Meintjes G, Calmy A, Bygrave H, Migone C, et al. (2018) Managing Advanced HIV Disease in a Public Health Approach. Clinical Infectious Diseases 66: S106–SS110. doi: 10.1093/cid/cix1139 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Hakim J, Musiime V, Szubert AJ, Mallewa J, Siika A, et al. (2017) Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa. New England Journal of Medicine 377: 233–245. doi: 10.1056/NEJMoa1615822 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Ahmed S, Autrey J, Katz IT, Fox MP, Rosen S, et al. (2018) Why do people living with HIV not initiate treatment? A systematic review of qualitative evidence from low- and middle-income countries. Soc Sci Med 213: 72–84. doi: 10.1016/j.socscimed.2018.05.048 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Adelekan B, Andrew N, Nta I, Gomwalk A, Ndembi N, et al. (2019) Social barriers in accessing care by clients who returned to HIV care after transient loss to follow-up. AIDS Res Ther 16: 17. doi: 10.1186/s12981-019-0231-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Kebaabetswe P, Manyake K, Kadima E, Auletta-Young C, Chakalisa U, et al. (2019) Barriers and facilitators to linkage to care and ART initiation in the setting of high ART coverage in Botswana. AIDS Care: 1–7. doi: 10.1080/09540121.2019.1640843 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Kerschberger B, Jobanputra K, Schomaker M (2019) Feasibility of antiretroviral therapy initiation under the treat-all policy under routine conditions: a prospective cohort study from Eswatini. 22: e25401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Kalyesubula R, Mutyaba I, Rabin T (2019) Trends of admissions and case fatality rates among medical in-patients at a tertiary hospital in Uganda; A four-year retrospective study. 14: e0216060. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Matoga MM, Rosenberg NE, Stanley CC, LaCourse S, Munthali CK, et al. (2018) Inpatient mortality rates during an era of increased access to HIV testing and ART: A prospective observational study in Lilongwe, Malawi. PLoS One 13: e0191944. doi: 10.1371/journal.pone.0191944 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Zolopa A, Andersen J, Powderly W, Sanchez A, Sanne I, et al. (2009) Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 4: e5575. doi: 10.1371/journal.pone.0005575 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Schafer G, Hoffmann C, Arasteh K, Schurmann D, Stephan C, et al. (2019) Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (toxoplasmosis, Pneumocystis jirovecii-pneumonia): a prospective, randomized, open-label multicenter study (IDEAL-study). AIDS Res Ther 16: 34. doi: 10.1186/s12981-019-0250-2 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Nei-yuan Hsiao

28 Oct 2021

PONE-D-21-11016Anti-retroviral Therapy Initiation and Outcomes Of Hospitalized HIV-infected Patients in Uganda - An Evaluation  of the HIV Test and Treat strategy.PLOS ONE

Dear Dr. Katende,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please address issues raised by the reviewers, particular around the first point raised by reviewer 2. Overall,  better contextualizing the  hospital admission population in the result and discussion is also needed.

Please submit your revised manuscript by Dec 12 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Nei-yuan Hsiao

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

3. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. 

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

4. Thank you for stating the following financial disclosure: 

"The author (AK) received funding for this work through Makerere University Implementation Science program: Building Implementation Science Capacity at Makerere University to Strengthen the Response to HIV/AIDS Epidemic in Uganda. This work was supported by the Fogarty International Center of the National Institutes of Health under Award Number D43 TW010037. Prof Moses R Kamya, (MRK) recevied this grant.  The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript" 

We note that one or more of the authors is affiliated with the funding organization, indicating the funder may have had some role in the design, data collection, analysis or preparation of your manuscript for publication; in other words, the funder played an indirect role through the participation of the co-authors. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors' salaries and/or research materials, please do the following:

a. Review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. These amendments should be made in the online form.

b. Confirm in your cover letter that you agree with the following statement, and we will change the online submission form on your behalf: 

“The funder provided support in the form of salaries for authors [insert relevant initials], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.

5. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. 

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

6. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Thank you for the opportunity to review this paper. It is a well-written manuscript that touches on an interesting and relevant topic. I have no major comments or suggestions for revisions. Some minor suggestions/comments:

1. Background: The authors might consider expanding on what we know about Test and Treat- a lot of work has been done to describe uptake and retention with Test and Treat policies (including Option B+). The authors could consider adding some of these details to provide a complete picture of how Test and Treat has been assessed thus far (challenges, successes, etc)

2. Could be interesting in any future work to conduct qualitative interviews with patients- specifically those who decline to start ART at the time of hospitalization. Data from the HCW interviews provide some insights into those who opt to start vs. those who do not. Interviews with patients would provide additional interesting insights.

3. The authors may consider providing details of what the current clinical recommendations are for those who are TB/HIV co-infected. In many clinical settings, there is confusion on this point with HCWs unclear on what the guidelines are or discomfort with shifting guidelines. In interviews with the HCWs- was it clear that they were providing clinical care that was in line with the current national or global guidelines?

Reviewer #2: This is a useful study of an important unanswered question around the timing of ART initiation in hospitalised HIV patients. The study group are medically complex and diverse, making it difficult to draw clear conclusions.

First 2 broad comments:

1. There are clear clinical contra-indications to immediate ART initiation in this group e.g. CCM, TB, critically ill, died as in your Table 3. This group should be removed from your analysis of 'factors associated with early ART'. i.e. The demographics, distance from home etc are only relevant to analysing the patient factors for deferring ART. Otherwise could be confounders. You don't discuss all the factors found significant on your Table 4, and I suspect many were chance findings as there isn't a plausible link that comes to mind. Eg, marital status? Please recheck Education figures, and no CI for employment?

2. In your discussion you have to highlight the fact that this was a pragmatic, observational study with the MAJOR confounder between the 2 groups being that those with TB, CCM and early death weren't initiated (appropriately). You shouldn't be tempted to draw any conclusions about lower mortality in a highly selected less sick group initiated early. It would require a carefully designed RCT to adequately answer this Q.

3. Table 2> What relevance are WBC, PLT, ALT, AST? Suggest omit

4. It would be useful to compare the primary reasons for admission/ final diagnosis between the Early ART & deferred groups if possible to help the reader understand this patient group.

5. "The proportion (95% confidence interval) of hospitalized patients with a new HIV

diagnosis who initiated ART during hospitalization was calculated as the number of

patients initiated on ART out of the total number of hospitalized patients with a new HIV

diagnosis admitted in the hospital during the study period." - Surely it's rather the total number recruited for the study?

Your qualitative aspect does raise some important programmatic issues.

only half having CD4 is a limitation

Thanks

Cl

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Aug 19;17(8):e0268122. doi: 10.1371/journal.pone.0268122.r002

Author response to Decision Letter 0


5 Feb 2022

Response to Reviewers

Comment: Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Response: Thank you for your comment; I have added one reference,

Kerschberger, B., Jobanputra, K., & Schomaker, M. (2019). Feasibility of antiretroviral therapy initiation under the treat-all policy under routine conditions: a prospective cohort study from Eswatini. 22(10), e25401. doi: 10.1002/jia2.25401

Comment: We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match.

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

Response: Thank you for your guidance

I agree with the following statement financial statement; “The funder provided support in the form of salaries for authors [FCS, AK], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section. This statement has been adapted in the funding source section page 18.

Comment: Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information:

Response: Captions of the supporting information files have been put.

S1 Table.

S2 STaTa data set

Reviewers’ comments

Comment: Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: No

Response: Thank you for your guidance

The anonymised quantitative data set has been uploaded as the supporting document. However the qualitative recordings and transcripts contains potentially sensitive information about the health care workers and their respective hospitals, this will be against the respective hospital ethical review boards and the Makerere University IRB. Attached is the contact for Makerere University IRB in case of further requests for qualitative data requests; rresearch9@gmail.com OR research@chs.mak.ac.ug

Comment: Could be interesting in any future work to conduct qualitative interviews with patients- specifically those who decline to start ART at the time of hospitalization. Data from the HCW interviews provide some insights into those who opt to start vs. those who do not. Interviews with patients would provide additional interesting insights.

Response: We thank you for this comment, we also acknowledge this as a limitation and surely patient interviews would provide additional insight.

Comment: The authors may consider providing details of what the current clinical recommendations are for those who are TB/HIV co-infected. In many clinical settings, there is confusion on this point with HCWs unclear on what the guidelines are or discomfort with shifting guidelines. In interviews with the HCWs- was it clear that they were providing clinical care that was in line with the current national or global guidelines?

Response: Thank you for this suggestion

The current WHO guidelines for initiation of ART among patients with HIV suspected to have TB should initiate ART as soon as possible. In those with confirmed TB, ART should be initiated as soon as possible within 2 weeks of starting Anti-TB drugs. Exception is made in patients suspected to have TB or cryptococcal meningitis; ART should be delayed at least until 4 weeks after initiating treatment. (Discussion, Page 16)

Comment: There are clear clinical contra-indications to immediate ART initiation in this group e.g. CCM, TB, critically ill, died as in your Table 3. This group should be removed from your analysis of 'factors associated with early ART'. i.e. The demographics, distance from home etc are only relevant to analysing the patient factors for deferring ART. Otherwise could be confounders.

Response: Thank you so much for this observation, we have removed TB, CCM from the multivariate analysis of 'factors associated with early ART'. Since Table 3 is rather a descriptive table, showing various reasons for deferring ART we kept them there.

Comment: You don't discuss all the factors found significant on your Table 4, and I suspect many were chance findings as there isn't a plausible link that comes to mind. Eg, marital status?

Response Thank you so much for this important suggestion, We have only discussed plausible factors like distance from health facility and education status, Discussion, page 16 and 17

Comment: Please recheck Education figures, and no CI for employment?

Response: Thank you for this observation

There is one patient who did not have an outcome (ART status at discharge), we put a foot note on table 4 (*) clarifying on the n= 110 instead of 111

These figures have now been corrected, thank you so much for the observation

The employment variable has no CI because it didn’t go to the multivariate model, we only provided CI to those that made it to the multivariate model

Comment: In your discussion you have to highlight the fact that this was a pragmatic, observational study with the MAJOR confounder between the 2 groups being that those with TB, CCM and early death weren't initiated (appropriately). You shouldn't be tempted to draw any conclusions about lower mortality in a highly selected less sick group initiated early. It would require a carefully designed RCT to adequately answer this Q.

Response: We acknowledge the short falls of the study design and we have stated that study was not powered to draw conclusions on the difference in the mortality in the limitation section, on page 17

Comment: Table 2> what relevance are WBC, PLT, ALT, AST? Suggest omit

Response: Thanks for the comment; these have been omitted as suggested

Comment: It would be useful to compare the primary reasons for admission/ final diagnosis between the Early ART & deferred groups if possible to help the reader understand this patient group.

Response: Data regarding reason of admission/diagnosis rather than TB and CCM, would be very heterogenic and hard to generalize. Since this was an observational study, many patients had more than one reason of admission collected in terms of presenting symptoms, but also multiple final diagnoses which most of them were clinically decided. This information would be very hard to generalize and this is another limitation of the study.

Comment: "The proportion (95% confidence interval) of hospitalized patients with a new HIV diagnosis who initiated ART during hospitalization was calculated as the number of patients initiated on ART out of the total number of hospitalized patients with a new HIV diagnosis admitted in the hospital during the study period." - Surely it's rather the total number recruited for the study?

Response: Thanks for the comment, we have made the changes as suggested on page 5

Comment: Your qualitative aspect does raise some important programmatic issues.

Response: Thank you so much , it a our honor

Comment: Only half having CD4 is a limitation

Thank you for this comment, this is acknowledged and reported as a limitation on page 17

Thank you so much

Attachment

Submitted filename: Response to Reviewers_PLOS_12_1_22.docx

Decision Letter 1

Nei-yuan Hsiao

25 Apr 2022

Anti-retroviral Therapy Initiation and Outcomes Of Hospitalized HIV-infected Patients in Uganda - An Evaluation  of the HIV Test and Treat strategy.

PONE-D-21-11016R1

Dear Dr. Katende,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Nei-yuan Hsiao

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Nei-yuan Hsiao

11 Aug 2022

PONE-D-21-11016R1

Antiretroviral Therapy Initiation and Outcomes Of Hospitalized HIV-infected Patients in Uganda - An Evaluation  of the HIV Test and Treat strategy.

Dear Dr. Katende:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Nei-yuan Hsiao

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. STaTa data set.

    (ZIP)

    S2 File. Health care worker interview guide.

    (DOCX)

    Attachment

    Submitted filename: Response to Reviewers_PLOS_12_1_22.docx

    Data Availability Statement

    Due to the small sample size and the detailed content of the interview transcripts, including sensitive and potentially identifying information. The Makerere University, school of Medicne research ethics committee does not approve public release of this type of data. However data supporting the findings of this study will be available upon reasonable request to the the corresponding author. All relevant quantitative data are within the manuscript and its Supporting information files. A quantitative data stata data set has been uploaded as Supporting information. Requests for Qualitative data can be sent to the Makerere School of Medicine Research Ethical Committee, rresearch9@gmail.com or research@chs.mak.ac.ug.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES